OR1L1

Across TCGA pan-cancer cohorts, OR1L1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR1L1 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OR1L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1L1 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

LUAD, COAD, and SCLC are the cancer types where OR1L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.090	0.788	<.001	40	view →
COAD	DFS	Median	All	0.480	0.786	.012	18	view →
SCLC	OS	Median	All	0.151	0.714	<.001	12	view →
KIRC	OS	Median	All	0.125	0.881	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.094	0.713	<.001	6	view →
STAD	DFS	Median	All	1.000	0.336	.045	1	view →
SKCM	OS	Median	All	0.535	0.286	.020	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR1L1–LUAD (OS)

Open the LUAD breakdown →